Intravenous Immunoglobulin in Acute Rheumatic Fever | Zendy

Lesley Voss | Zendy; Nigel Wilson | Zendy; John M. Neutze | Zendy; R. M. L. Whitlock | Zendy; Rohan Ameratunga | Zendy; Lloyd Cairns | Zendy; Diana Len | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravenous Immunoglobulin in Acute Rheumatic Fever

Author(s) -

Lesley Voss,

Nigel Wilson,

John M. Neutze,

R. M. L. Whitlock,

Rohan Ameratunga,

Lloyd Cairns,

Diana Len

Publication year - 2001

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.103.3.401

Subject(s) - medicine , carditis , placebo , erythrocyte sedimentation rate , rheumatic fever , gastroenterology , pathology , alternative medicine

Acute rheumatic fever (ARF) remains the leading cause of acquired heart disease in children worldwide. No therapeutic agent has been shown to alter the clinical outcome of the acute illness. Immunological mechanisms appear to be involved in the pathogenesis of ARF. Intravenous immunoglobulin (IVIG), a proven immunomodulator, may benefit cardiac conditions of an autoimmune nature. We investigated whether IVIG modified the natural history of ARF by reducing the extent and severity of carditis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research